

(43) International Publication Date
3 March 2011 (03.03.2011)(10) International Publication Number
WO 2011/025546 A1

(51) International Patent Classification:

C07D 249/06 (2006.01) **G01N 33/58** (2006.01)
C12Q 1/48 (2006.01) **C07D 403/02** (2006.01)

(74) Agent: OYER, Timothy, J.; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210-2206
(US).

(21) International Application Number:

PCT/US2010/002384

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

31 August 2010 (31.08.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/238,601 31 August 2009 (31.08.2009) US

(71) Applicant (for all designated States except US): MAS-
SACHUSETTS INSTITUTE OF TECHNOLOGY
[US/US]; 77 Massachusetts Avenue, Cambridge, MA
02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): IMPERIALI, Bar-
bara [US/US]; 58 Porter Road, Cambridge, MA 02140
(US). LUKOVIC, Elvedin [US/US]; 32 Willow Street,
Cambridge, MA 02141 (US). GONZALEZ-VERA,
Juan, Antonio [ES/ES]; Av De La Constitucion 9,
E-02139 Granada (ES).

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: 1, 2, 3-TRIAZOLE CONTAINING PROTEIN KINASE SENSORS

(57) Abstract: The present invention generally relates to compositions and methods for determining kinase activity. In some cases, the compositions comprise a triazole heterocycle. In some embodiments, the compositions comprise a quinoline moiety. In one aspect, the present invention is directed to compositions that undergo chelation-enhanced fluorescence (CHEF). In some cases, the compositions may have fluorescence emission spectra with peak maxima greater than 490 nm. The compositions of the present invention can be used, in certain embodiments, to detect phosphorylated substrates and biological processes such as phosphorylation events.




Fig. 2



Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

1, 2, 3-TRIAZOLE CONTAINING PROTEIN KINASE SENSORS

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Serial
5 No. 61/238,601, filed August 31, 2009, entitled "Kinase Sensors," by Imperiali et al.,
which is incorporated herein by reference.

FEDERALLY SPONSORED RESEARCH

Research leading to various aspects of the present invention were sponsored, at
10 least in part, by the National Institutes of Health, Grant No. U54 GM064346. The
United States Government has certain rights in the invention.

FIELD OF INVENTION

The present invention generally relates to compositions and methods for
15 determining phosphorylation activity.

BACKGROUND

The ubiquitous process of protein phosphorylation is central to signal
transduction and regulation in living organisms. By catalyzing transfer of the γ -
20 phosphoryl group of ATP to the side chains of serine, threonine, and/or tyrosine, protein
kinases play an important role in regulating many aspects of cellular function in
eukaryotes, including proliferation, cell cycle, metabolism, transcription, and apoptosis.
Not surprisingly, protein kinases have also emerged as attractive targets for drug
discovery, since many are associated with a wide variety of diseases, from cancer to
25 inflammation. Thus, tools that allow for facile monitoring of kinase activity are in great
demand in both pharmaceutical and academic settings.


SUMMARY OF THE INVENTION

The present invention provides improvements in compositions and methods for
30 determining kinase activity, in particular, protein kinase activity. The invention involves
compositions and techniques that facilitate fluorescence-based sensing of kinase activity
at electromagnetic radiation emission wavelengths longer (lower in energy) than

- 2 -


advantages. First, longer emission wavelengths can result in easier detection because the sensing emission wavelength is separated from, or at least less obscured by or overlapping with, background signals typically present in an environment where sensing is desired. Second, emission at longer wavelengths, whether *in vivo*, or *in vitro* in the presence of tissue, can reduce what might otherwise cause damage to tissue and/or other species because of the lower energy of emission and/or lower adsorption of the emission by tissue and/or other species. The invention involves development of a class of novel compositions of matter which can form the basis of sensing compositions and techniques. The invention also provides compositions and techniques for kinase sensing including a class of molecules some members of which are known in the prior art but are not known for use in kinase sensing. The invention also provides the general ability to engage in kinase sensing via emission at longer wavelengths than is known in the prior art.

In some embodiments, compositions are provided. The compound may comprise a compound having a structure as in formula (I):



where R₁ and R₂ are each independently hydrogen or aryl, or where R₁ and R₂ together with the carbon atoms of the triazole ring to which they are connected form a ring; R₃ is independently hydrogen, alkyl, aryl, halo, or hydroxyl, amino, thiol, sulfonic acid, sulfonamide or a substituted derivative thereof, wherein R₃ can substitute any open valence of any ring within structure (I); m is 1, 2, 3, 4, or 5; and R₄ is hydroxyl, amino, thiol, or a substituted derivative thereof.

In some embodiments, the compound may have a structure as in formula (II):



where R₁ and R₂ are each independently hydrogen or aryl, or where R₁ and R₂ together with the carbon atoms of the triazole ring to which they are connected form a

- 3 -

ring; and R₃ comprises i) a species capable of fluorescing, and ii) a protein kinase substrate or at least one amino acid.

Various methods are also provided. In some embodiments, the method comprises determining phosphorylation of a protein kinase substrate using fluorescence of a composition, wherein the composition has a fluorescence emission maximum greater than 490 nm. In some embodiments, the method comprises determining phosphorylation of a protein kinase substrate using fluorescence of a composition, wherein the composition has a fluorescence extinction coefficient greater than 1000 M⁻¹ cm⁻¹ at a fluorescence emission wavelength greater than 490 nm. In some embodiments, the method comprises determining phosphorylation of a protein kinase substrate using fluorescence of any composition described herein.

Other advantages and novel features of the present invention will become apparent from the following detailed description of various non-limiting embodiments of the invention when considered in conjunction with the accompanying figures. In cases where the present specification and a document incorporated by reference include conflicting and/or inconsistent disclosure, the present specification shall control. If two or more applications incorporated by reference include conflicting and/or inconsistent disclosure with respect to each other, then the later-filed application shall control.

BRIEF DESCRIPTION OF THE DRAWINGS

Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying figures, which are schematic and are not intended to be drawn to scale. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For the purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention. In the figures:

FIG. 1 shows a table of fluorescence data for various prior art compositions.

FIG. 2 shows the synthesis of various compositions described herein via a 1,3-dipolar cycloaddition reaction.

FIG. 3 shows qualitative comparison of emission wavelengths of various compositions.

- 4 -

FIG. 4 shows the synthesis of a protein kinase sensor, according to one embodiment of the invention.

FIG. 5 shows a table of substrate sequences of RDF chemosensors and fluorescence increases.

5 FIG. 6 shows (a) spectral characterization and (b) enzymatic evaluation of various Clk-based substrates.

FIG. 7 shows a table of characterization data for various peptides.

FIG. 8 shows a table of fluorescence properties for various compositions described herein.

10 FIG. 9 shows a spectral comparison of phosphorylated and unphosphorylated peptides.

FIG. 10 shows NMR spectra for 5-carbaldehyde-8-hydroxy-2-methylquinoline (2), according to an embodiment;

15 FIG. 11 shows NMR spectra for 5-carbonitrile-8-hydroxy-2-methylquinoline (3), according to an embodiment;

FIG. 12 shows proton (top) and carbon (bottom) NMR spectra for 1-(8-Hydroxy-2-methylquinolin-5-yl)ethanone (4).

FIG. 13 shows proton (top) and carbon (bottom) NMR spectra for 8-Hydroxy-2-methylquinoline-5-Carbonyl chloride (5).

20 FIG. 14 shows NMR spectra for 5-Azido-8-hydroxy-2-methylquinoline (13), according to an embodiment;

FIG. 15 shows proton (top) and carbon (bottom) NMR spectra for 5-Azido-8-tert-butylidiphenylsilyloxy-2-methylquinoline (14).

25 FIG. 16 shows the proton NMR spectrum for 5-Azido-2-bromomethyl-8-tert-butylidiphenylsilyloxyquinoline (15).

FIG. 17 shows proton (top) and carbon (bottom) NMR spectra for 8-Hydroxy-5-(4-cyclohexenyl-1H-1,2,3-triazol-1-yl)quinoline (10a).

FIG. 18 shows proton (top) and carbon (bottom) NMR spectra for 8-Hydroxy-5-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline (10b).

30 FIG. 19 shows proton (top) and carbon (bottom) NMR spectra for 8-Hydroxy-5-(4-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)quinoline (10c).

- 5 -

FIG. 20 shows proton (top) and carbon (bottom) NMR spectra for 8-Hydroxy-5-(4-(3-chlorophenyl)-1H-1,2,3-triazol-1-yl)quinoline (**10d**).

FIG. 21 shows proton (top) and carbon (bottom) NMR spectra for 8-Hydroxy-5-(4-p-tolyl-1H-1,2,3-triazol-1-yl)quinoline (**10i**).

5 FIG. 22 shows proton (top) and carbon (bottom) NMR spectra for 8-Hydroxy-5-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)quinoline (**10u**).

Other aspects, embodiments and features of the invention will become apparent from the following detailed description when considered in conjunction with the accompanying drawings. The accompanying figures are schematic and are not intended
10 to be drawn to scale. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention. All patent applications and patents incorporated herein by reference are incorporated by reference in their entirety. In case of conflict, the present specification,
15 including definitions, will control.

DETAILED DESCRIPTION

The present invention generally relates to compositions and methods for determining kinase activity, using electromagnetic emission at longer wavelengths
20 (lower in energy) than previously reported.

As noted above, various classes of compositions are provided, including those that can undergo chelation-enhanced fluorescence (CHEF). In some cases, the compositions may have fluorescence emission spectra with peak maxima greater than 490 nm, and/or a fluorescence extinction coefficient greater than $1000 \text{ M}^{-1} \text{ cm}^{-1}$ at a
25 fluorescence emission wavelength greater than 490 nm. The compositions of the present invention can be used, in certain embodiments, to detect phosphorylated substrates and biological processes such as phosphorylation events. One class of compositions of the invention includes a triazole heterocycle-based structure coupled to a species capable of fluorescing, where the triazole heterocycle-based structure affects electromagnetic
30 radiation emission such that longer wavelength, lower energy emission results. Another class of molecules includes a quinoline moiety based structure that provides the molecule

- 6 -

with fluorescent capability, which can be used as a kinase sensor at longer wavelength/lower energy emission as described herein.


In some embodiments, the present invention provides compositions for the detection of a phosphorylated substrate. The composition may comprise a luminescent species, such as a species capable of generating a fluorescence emission (e.g., fluorophore). The fluorophore may be any species capable of generating a fluorescent signal upon exposure to an external source of energy (e.g., electromagnetic radiation, a chemical reagent, etc.). As noted above, some embodiments may advantageously provide compositions which exhibit a red-shifted fluorescence emission, i.e., a fluorescence emission shifted to longer, lower energy wavelengths. For example, the species may comprise a group which extends the pi-conjugation of the luminescent species, thereby reducing the pi-pi* gap and causing a red-shift in emission. In some cases, the luminescent species may include one or more electron-rich groups, such as amino, hydroxy, alkoxy, acylamino, acyloxy, alkyl, halide, electron-rich aryl groups (e.g., triazoles), and the like, such that the composition exhibits fluorescence excitation and emission at longer wavelengths.

In some cases, the composition has a fluorescence emission maximum greater than 490 nm, greater than 500 nm, greater than 510 nm, greater than 520 nm, greater than 530 nm, greater than 540 nm, greater than 550 nm, greater than 600 nm, or, in some cases, greater.

In some embodiments, the composition may also include a phosphorylation site, including a hydroxyl group and hydroxyl-containing amino acid residues, such as serine, threonine and tyrosine. Without wishing to be bound by theory, a phosphorylated sensor or composition may have increased affinity for a metal, such as Mg^{2+} , and upon binding the metal, the fluorescence of the sensor may be enhanced by a phenomenon known in art as chelation-enhanced fluorescence (CHEF). In some embodiments, the enhanced fluorescence may be measured and used to monitor and/or quantify phosphorylation, as discussed in more detail below.

In one set of embodiments, the composition may comprise a compound comprising a triazole ring. For example, the composition may comprise a compound having a structure as in formula (I),


- 7 -



wherein R^1 and R^2 can be the same or different and are each independently hydrogen, alkyl, aryl, heteroaryl, carbocyclic, or heterocyclic, or where R^1 and R^2 are joined together to form a ring; R^3 , R^4 , R^5 , R^6 , and R^7 can be the same or different and are each independently hydrogen, alkyl, aryl, heteroaryl, halo, hydroxyl, amino, thiol, sulfonic acid, sulfonamide, or a substituted derivative thereof; and R^8 is hydroxyl, amino, thiol, or a substituted derivative thereof. In some cases, R^1 and R^2 are each independently hydrogen, aryl, or heterocyclyl, such as phenyl, pyridinyl, imidazolyl, thiophenyl, naphthyl, or the like, any of which may be optionally substituted. In some embodiments, R^1 and R^2 are joined together with the carbon atoms of the triazole ring to which they are connected form a ring, including a carbocyclic or heterocyclic ring, which may optionally include one or more alkenyl or alkynyl groups. The ring may be, for example, a 5-, 6-, 7-, or 8-membered ring, optionally substituted.

In some embodiments, at least one of R^3 , R^4 , R^5 , R^6 , and R^7 comprises at least one amino acid or a protein kinase substrate. In some embodiments, at least one of R^3 , R^4 , R^5 , R^6 , and R^7 contains a functional group capable of reacting with a molecule such as an amino acid or protein kinase substrate. In some cases, R^4 , R^5 , R^6 , and R^7 are each hydrogen. In some embodiments, R^8 is hydroxyl. In certain embodiments, R^1 may be cyclohexenyl, phenyl, bis-trifluoromethylphenyl, bromophenyl, chlorophenyl, fluorophenyl, tosyl, cyanophenyl, methoxyphenyl, toluoyl, pentylphenyl, imidazolyl, thiophenyl, aminophenyl, pyridinyl, dimethylaminophenyl, naphthalenyl, methoxynaphthalenyl, etc. In some instances, R^2 is hydrogen. In some examples, R^3 comprises at least one amino acid or a protein kinase substrate.


In another set embodiments, the composition may comprise a compound having a structure as in formula (II),



- 8 -

wherein R^1 and R^2 can be the same or different and are each independently hydrogen, alkyl, aryl, heteroaryl, carbocyclic, or heterocyclic, or where R_1 and R_2 are joined together to form a ring; and R^9 comprises (i) a fluorophore or a species capable of fluorescing and (ii) a protein kinase substrate or at least one amino acid. In some
 5 embodiments, the species may be a compound capable of chelation-enhanced fluorescence, such as a quinoline structure. The protein kinase substrate or at least one amino acid may be a substituent of the species capable of fluorescing and may be connected directly or with a linker (i.e., a hydrocarbon chain, polyethyleneglycol, a polymer, etc.).

10 In another embodiment, a composition of the present invention may comprise a compound having a structure as in formula (III),




wherein R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , and R^{16} can be the same or different and are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxyl,
 15 amino, thiol, sulfonic acid, sulfonamide, azido, or a substituted derivative thereof.

In some embodiments, at least one of R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , and R^{16} may be selected to be conjugated (e.g., pi-conjugated) with the quinoline moiety of formula (III). In some cases, at least one of R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , and R^{16} comprises a protein kinase substrate or at least one amino acid. In some cases, at least one of R^{10} , R^{11} , R^{12} ,
 20 R^{13} , R^{14} , R^{15} , and R^{16} comprises a functional group capable of forming a chemical bond with a molecule, such as a protein kinase substrate or amino acid. In some cases, R^{10} comprises a protein kinase substrate or at least one amino acid. In some cases, at least one of R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , and R^{16} is hydroxyl, amino, thiol, or a substituted derivative thereof. For example, in some embodiments, R^{16} is hydroxyl, amino, thiol, or
 25 a substituted derivative thereof. In some instances, R^{13} comprises a group (e.g., a triazole group) that is conjugated with the quinoline moiety of formula (III).

In some embodiments, R^{13} is alkynyl, and R^{10} comprises a protein kinase substrate or at least one amino acid.

In one embodiment, the compound has the following structure,

- 9 -



wherein “~” comprises a protein kinase substrate or at least one amino acid.


Some embodiments of the invention may include one or more groups that can be further altered (e.g., reacted) such that a new functional group (e.g., atom or chemical group) is formed. In one set of embodiments, the composition may include a group
 5 capable of reacting via a 1,3-dipolarcycloaddition reaction, i.e., via “click chemistry.” For example, the composition may comprise a dipolarophile group (e.g., an alkyne) that is reacted with a 1,3-dipolar compound. Alternatively, the composition may comprise a 1,3-dipolar compound (e.g., an azido group) that is reacted with a dipolarophile. The
 10 1,3-dipolar cycloaddition reaction may be performed under conditions that may be unreactive to the remainder of the compound, other than the dipolarophile or 1,3-dipolar compound. In an illustrative embodiment, the composition may contain an azido group, which may be further reacted with an alkyne to form a triazole group. In some
 15 embodiments, the molecule capable of fluorescing may comprise an azido group, where the azido group may be reacted with an alkynyl-containing compound to generate a fluorophore. Such a strategy may be useful, for example, for incorporating compositions described herein into a peptide structure, as described more fully below. Those of
 ordinary skill in the art would be able to select the appropriate reaction conditions and additives suitable for a particular 1,3-dipolar cycloaddition reaction. Methods for
 20 performing 1,3-dipolar cycloaddition reactions are also described, for example, in Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products, A. Padwa, W. H. Pearson, Wiley-Interscience, 2002, the contents of which are incorporated herein by reference.

In some cases, intermediate compounds comprising azido groups are provided.
 25 For example, a composition may comprise a compound having a structure as in formula (III), wherein at least one of R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , and R^{16} is azido, and at least one

- 10 -

of R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, and R¹⁶ is hydroxyl, amino, thiol, or a substituted derivative thereof, and/or is capable of reacting with a functional group of an amino acid.

In some embodiments, the intermediate compound has the following formula,



5 wherein R¹⁰, R¹¹, R¹², R¹⁴, R¹⁵, and R¹⁶ are as defined above.

Some embodiments of the invention provide proteins or peptides substituted with compositions as described herein. For instance, an amino acid residue on a protein, such as cysteine, aspartic acid, glutamic acid, or lysine, may be well-suited for reaction with any of the compounds described herein. Such substituted peptides may be useful for a
10 wide variety of applications, such as kinase sensing or other fluorescent sensing applications, as the compound may retain substantially all of its fluorescence even when attached to the peptide. For example, the substituted peptides may be useful as fluorescent probes for various biological applications. As a specific example, compounds such as those of formulae (I), (II), and/or (III), can be attached to peptides
15 using standard peptide synthesis methods (solid phase or solution phase), such as those described in, for example, *Fmoc Solid Phase Peptide Synthesis – A Practical Approach*, Oxford University Press, 2003, Eds W. C. Chan and P. D. White (ISBN 0 19 963 724 5) and *The Chemical Synthesis of Peptides*, Clarendon Press, Oxford, 1994, Jones, J. (ISBN 0 19 855839 2).

20 Compounds of the present invention, including peptides substituted with compositions described herein, can be used in a various methods (e.g., methods for determining kinase activity). Methods for the determination of analytes may comprise exposure of a composition described herein to a sample suspected of containing an analyte, and, if present, the analyte interacts with the composition to cause a change in a
25 signal of the composition (e.g., an optical signal). As used herein, the term “determining” generally refers to the analysis of a species or signal, for example, quantitatively or qualitatively, and/or the detection of the presence or absence of the species or signals. “Determining” may also refer to the analysis of an interaction between two or more species or signals, for example, quantitatively or qualitatively,
30 and/or by detecting the presence or absence of the interaction. In some cases,

- 11 -

determination of the analyte is performed *in vivo*. In some cases, determination of the analyte is performed *in vitro*.

In some embodiments, the analyte may interact with the composition to cause a change in affinity (e.g., binding affinity) of the composition for another species (e.g., metal ion) and/or a change in an optical signal of the composition, which may then determine the analyte. In some cases, the method may involve determining phosphorylation of a protein kinase substrate using fluorescence of the compositions described herein, wherein the composition has a fluorescence emission maximum greater than 490 nm. In some cases, the composition may have a fluorescence extinction coefficient greater than $1000 \text{ M}^{-1} \text{ cm}^{-1}$ at a fluorescence emission wavelength greater than 500 nm. For example, the composition may include a protein kinase substrate having a first fluorescence emission, wherein interaction of the composition with an analyte generates a determinable change or shift in the fluorescence emission, thereby indicating the presence and/or amount of the analyte.

In some embodiments, the method may comprise providing a composition as described herein, wherein the composition comprises a phosphorylation site and a compound capable of fluorescing upon chelation of a metal, and exposing the composition to a sample comprising Mg^{2+} , a phosphoryl donor (e.g., ATP), and a kinase. Upon exposure to the sample, the composition may become phosphorylated to form a product having increased affinity for Mg^{2+} . The phosphorylated product may then bind Mg^{2+} , resulting in an enhancement of fluorescence via chelation-enhanced fluorescence (CHEF). The fluorescence of the composition may then be analyzed to determining the presence and/or amount of a phosphorylated product.

Methods described herein may be performed *in vitro* or *in vivo*. For *in vitro* applications, the reaction is typically conducted in a buffer containing Mg^{2+} and a phosphoryl donor. Suitable buffers include, for example, HEPES and TRIS. One possible Mg^{2+} source is MgCl_2 . One possible phosphoryl donor is ATP. For *in vitro* applications, the concentration of kinase can range from about 0.5 nM to about 1 micromolar, in some cases not more than about 500 nM, and in some cases not more than about 250 nM. The concentrations of sensor can vary, but is usually ranges between about 0.1 μM to 10 mM. Adenosine 5'-triphosphate (ATP) may be used as the phosphoryl donor, in stock solutions of about 10-100 mM. Saturating concentrations of

- 12 -

ATP may be used to arrive at values of K_m and V_{max} for the substrates. For in vivo applications, when the sensor is internalized into a cell, sufficient kinases, Mg^{2+} , and phosphate donors exist in the cytosol. For in vivo sensing, a cellular internalization sequence can be included in the sensor design. Suitable cellular internalization sequences include Penetratins, HIV-Tat domains and poly-arginine sequences.

In one set of embodiments, compositions and methods for monitoring and/or imaging species associated with kinase or phosphorylation activity are provided. As used herein, "species associated with kinase or phosphorylation activity" refer to any species that triggers (e.g., catalyzes), initiates, performs, or otherwise promotes the transfer of a phosphate group to and/or from a substrate. The species may be an enzyme, such as a kinase (e.g. mitogen-activated protein kinase-activated protein kinase-2 (MK2), sarcoma kinase (Src), Ser/Thr and Tyr kinases) or a phosphatase, a small molecule (e.g., ATP), an ion (e.g., Mg^{2+}), or other species. In some cases, the species may phosphorylate or de-phosphorylate a portion of the compositions described herein. For example, a compound comprising a fluorophore and a protein kinase substrate or at least one amino acid may be exposed to a sample containing a kinase, such that the compound can be recognized by and/or may be phosphorylated by the kinase.

Various kinases may be analyzed using methods described herein. For example, serine/threonine and tyrosine kinases can be used in the present invention. Other exemplary kinases include cAMP dependent protein kinase, protein kinase C, Ca/calmodulin dependent kinases, AMP activated kinase, s6 kinases, eIF-2 kinases, p34.sup.cdc2 protein kinase, mitogen activated protein kinases, casein kinase-2, casein kinase-1, glycogen sythase kinase-3, Tyr-specific protein kinases. For applications in which the kinase is dependent on cofactors, a source of cofactor may also be included in the sample. For example, for PKC, sources of Ca^{2+} , phospholipid, and diacylglycerol may be used.

The compositions described herein may also be useful as fluorescence probe molecules in monitoring biological interactions. Biological interactions play important roles in the sequence and mechanisms of action of various cellular processes and signal pathways. Accordingly, the time course, nature, and sequence of the different cellular processes can be elucidated by *in situ* observation using certain compositions of the present invention. Specific inhibitors and/or activators of the cellular processes and

- 13 -

signal pathways may optionally be used in addition to compounds of the present invention.

In some cases, the method may involve exposing a composition as described herein to a target molecule (e.g., a peptide), and determining the fluorescence of the biological sample at various stages during a biological event or interaction. The compound may be a peptide substituted with a composition as described herein. In some cases, the compound may be a peptide containing an amino acid residue that is modified by composition as described herein.

The fluorescence of the compositions may be analyzed or measured using methods known in the art. In some cases, the intensity and/or wavelength of the emitted fluorescent energy may determine the presence or amount of analyte in the same, or may provide other information about the sample. The composition/sample may be exposed to electromagnetic radiation having a wavelength of about 375 nm or greater. In some embodiments, the composition/sample may be exposed to electromagnetic radiation having a wavelength between about 375 nm and about 700 nanometers nm, between about 490 nm and about 700 nanometers nm, between about 520 nm and about 700 nm, or between about 500 nm and about 600 nm, among other ranges.

In some cases, the fluorescence of a molecule may be defined by the quantum yield. The quantum yield is the ratio of the photons absorbed by the compound to the photons emitted through fluorescence by the compound. Compounds of the present invention have quantum yields that may be relatively low in aqueous solutions, but higher in non-polar environments. Quantum yields for various embodiments may range from about 0.001 and about 0.8, or between about 0.001 and about 0.005 for non-chelated compounds, or between about 0.1 and about 0.8 for chelated compounds. The fluorescence can also be evaluated by determining the dipole moment change between the ground and excited state. The change in the dipole moment can be estimated from a plot of the Stokes shift vs. the orientation polarizability, known as a Lippert-Mataga plot, known to those of ordinary skill in the art. As fluorescence can be sensitive to the pH of the surrounding environment, certain compositions of the present invention are useful as fluorescence probes or sensors in the pH range from about 4 to about 8.

The concentration of the composition used may depend on external factors such as the detection equipment. Typically, the concentration of the composition in the

- 14 -

sample is from greater than about 0.1 nM. A sensor of various embodiments of the present invention can be used in a method for detecting biological interactions. The methods of certain embodiments of the present invention include providing a peptide incorporating an amino acid comprising a compound of formula (I), (II), or (III),
5 contacting a target molecule with the peptide to form a biological sample, and monitoring the fluorescence of the biological sample.

As described herein, some embodiments of the invention provide proteins or peptides substituted with compounds as described herein, where the compound may be attached to the peptides either during or after peptide synthesis. In some embodiments,
10 the peptide may be first synthesized with protecting groups on the side chains of the peptide. Upon selective removal of certain protecting groups, the compound can be coupled to the side chains of the peptides using standard coupling methods. For example, when (I), (II), or (III) comprise a halo alkyl group (i.e., bromomethyl), the compound can be coupled to a residue containing a thiol group in its side chain (such as
15 Cys) forming a thioether linkage. In another example, when (I), (II), or (III) comprise an amine, the amine can be coupled to a residue containing a carboxylic acid in its side chain (such as Asp or Glu), forming an amide linkage. Also, when (I), (II), or (III) comprise a thiol, the thiol can be coupled to a residue containing a thiol group in its side chain (such as Cys), forming a disulfide linkage. In another embodiment, when (I), (II),
20 or (III) comprise a carboxylic acid, the carboxylic acid can be coupled to a residue containing an amine in its side chain. In another example, when (I), (II), or (III) comprise an aldehyde, it can be coupled to a residue containing an amine via reductive amination. The fluorophore-containing peptide may then be deprotected and purified in some cases.

25 In some embodiments, a triazole structure may be incorporated into a compound after the compound is coupled to a peptide. For example, the compound may comprise an azido group that can be reacted with an alkyne to form a triazole after the compound is coupled to a peptide. Such an approach may be advantageous, for example, for creating a library of modified peptides, with each peptide containing a compound that
30 has been reacted with a different alkyne.


Selective deprotection of amino acids is well known in the art. One method is to use orthogonal side-chain protection such as allyl (OAll) (for the carboxyl group in the

- 15 -


side chain of glutamic acid or aspartic acid, for example), allyloxy carbonyl (Alloc) (for the amino nitrogen in the side chain of lysine or ornithine, for example), p-methoxytrityl (MMT) or acetamidomethyl (Acm) (for the sulfhydryl of cysteine). OAlI and Alloc are easily removed by Pd, Acm can be removed by iodine treatment, and MMT can be removed by mild acid treatment.

Methods for introduction and removal of N-protecting groups are known to those skilled in the art, examples of which are disclosed in Greene and Wuts, *Protective Groups in Organic Synthesis*, 2nd ed.; John Wiley & Sons, New York, 1991.

As a non-limiting example, a peptide may be reacted with a compound of formula (IV):



Such a reaction may produce, in some embodiments, peptides having an amino acid residue of formula (V):



The peptide to be modified may be any suitable peptide, for example, naturally occurring, artificial or synthetically produced, etc. As a specific example, a peptide may be a peptide that comprises a target recognition sequence, such as an SH2-domain recognition sequence. Examples of SH2-domain recognition sequences include, but are not limited to, pTyr-Asp-His-Pro or pTyr-Glu-Asn-Val.

Examples of synthesis techniques are discussed in the examples, below, and those of ordinary skill in the art will be able to readily modify such techniques as needed in order to reach a particular structure without an undue amount of experimentation. In some cases, a composition of the invention is synthesized using a commercially-available anhydride as a starting material. In some cases, various protecting groups may be utilized in the synthesis of the compositions. The phrase "protecting group" as used

- 16 -

herein refers to temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 2nd ed.; Wiley: New York, 1991). Any of the compositions described herein may be substituted with one or more protecting groups.

Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are listed here.

The term "hydroxy" is given its ordinary meaning in the art and refers to an -OH group.

The term "amino" is given its ordinary meaning in the art and refers to a -NR'R'' group, where R' and R'' are each independently hydrogen or alkyl.

The term "thiol" is given its ordinary meaning in the art and refers to a -SR' group, where R' is hydrogen.

The term "halogen" or "halo" is given its ordinary meaning in the art and refers to a chlorine, bromine, iodine, or fluorine atom.

The term "alkyl" means a hydrocarbon group that may be linear, cyclic, or branched or a combination thereof having the number of carbon atoms designated (i.e., C1-8 means one to eight carbon atoms). An alkyl group may be saturated or unsaturated. Unsaturated alkyl groups may be conjugated, partially conjugated, or unconjugated. "Conjugated" as used herein in the context of unsaturated groups has its ordinary meaning as known in the art. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, cyclopentyl, (cyclohexyl)methyl, cyclopropylmethyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc. Alkyl groups can be substituted or unsubstituted, unless otherwise indicated. Examples of substituted alkyl groups include haloalkyl, thioalkyl, aminoalkyl, and the like.

The term "aryl" means a polyunsaturated, aromatic hydrocarbon group having a single ring (monocyclic) or multiple rings (bicyclic or polycyclic), which can be fused together or linked covalently. Examples of aryl groups include phenyl and naphthalene-

- 17 -

1-yl, naphthalene-2-yl, biphenyl and the like. Aryl groups can be substituted or unsubstituted, unless otherwise indicated.

The term "azido" is given its ordinary meaning in the art and refers to an -N₃ group.

5 The term "heteroaryl" means an aromatic group containing at least one heteroatom, where the heteroaryl group may be monocyclic or bicyclic. Examples include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indoliziny, 10 benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiazolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl or thienyl.

15 The term "heterocyclyl" or "heterocyclic," which are synonymous as used herein, means a saturated or unsaturated ring containing at least one heteroatom (typically 1 to 5 heteroatoms) selected from nitrogen, oxygen or sulfur. The heterocyclyl ring may be monocyclic or bicyclic. Examples of heterocycle groups include pyrrolidine, piperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine, 20 thiomorpholine-S-oxide, thiomorpholine-S,S-dioxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine and the like.

The term "ring" means a compound whose atoms are arranged in formulas in a cyclic form. The ring compound can be either carbocyclic or heterocyclic.

25 The term "carbocyclic" means a ring composed exclusively of carbon atoms.

The term "substituent" means an atom or a group that replaces another atom or group in a molecule.

30 The terms "N-terminal protecting group" or "N-protecting group" refer to a group that prevents undesirable reaction of the amino functional group during subsequent transformations. The use of N-protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure and many such protecting groups are known. Commonly used N-protecting groups are known to those

- 18 -

skilled in the art, examples of which are disclosed in Greene and Wuts, Protective Groups in Organic Synthesis, 2nd ed.; John Wiley & Sons, New York, 1991). Examples of N-protecting groups include, but are not limited to, benzyl, substituted benzyl, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (Fmoc), trityl, N-veratylloxycarbonyl (N-Voc), N-allyloxycarbonyl (N-Alloc) and N-pentenoyl (N-Pent), acyl groups including formyl, acetyl (Ac), trifluoroacetyl, trichloroacetyl, propionyl, pivaloyl, t-butylacetyl, acylisothiocyanate, aminocaproyl, benzoyl and the like; acyloxy groups, including t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), p-methoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, allyloxycarbonyl and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like; arylalkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl groups such as trimethylsilyl, t-butyldimethylsilyl and the like.

The term "C-terminal protecting group" refers to a group that prevents undesirable reaction of the carboxyl functional group and includes, but is not limited to, C₁-C₁₂ alkyl (e.g., tert-butyl) and C₁-C₁₂ haloalkyl.

The term "chelation-enhanced fluorescence (CHEF)" means fluorescence enhancement of a compound as a result of metal ion binding (chelation) to that compound.

The term "capping group" means a chemical group connected to the N- or C-terminus of a peptide to prevent the peptide from degrading.

"Alkoxy" refers to -O-alkyl. Examples of an alkoxy group include methoxy, ethoxy, n-propoxy, etc.

"Haloalkyl," as a substituted alkyl group, refers to a monohaloalkyl or polyhaloalkyl group, most typically substituted with from 1-3 halogen atoms. Examples include 1-chloroethyl, 3-bromopropyl, trifluoromethyl and the like.

All of the above terms (e.g., "alkyl," "aryl," "heteroaryl" etc.), in some embodiments, include both substituted and unsubstituted forms of the indicated groups. These groups may be substituted multiple times, as chemically allowed. Suitable substituents include alkyl, aryl, heteroaryl, heterocyclyl, halogen, alkoxy, oxygen, and nitrogen.

- 19 -

Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, both solvated forms and unsolvated forms are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms (i.e., as polymorphs). In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention. The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

“Fluorescence” encompasses the release of fluorescent energy. Less broadly, the term “fluorescence” refers to fluorescent emission, the rate of change of fluorescence over time (i.e., fluorescence lifetime), fluorescence polarization, fluorescence anisotropy, and fluorescence resonance energy transfer. See Eftink, M. R., Biophysical J. 66:482-501 (1994).

“Fluorescence probe molecule” refers to a compound of the present invention. The compound, after excitement by light of a defined wavelength or defined range of wavelengths, is capable of emitting fluorescent energy. The fluorescent molecule or a compound may be capable of binding to a peptide, protein, membrane or receptor.

The term “biological interactions” encompasses the interaction of a compound or molecule with a target molecule.

“Protein” and “peptide,” as used herein, are synonymous. The peptide may comprise any number of amino acids. For instance, the peptide of the present invention may comprise 2-100 amino acids, 2-30 amino acids, 2-20 amino acids, or 3-10 amino acids. For proteins or peptides, the term “unfolding” encompasses any change in

- 20 -

structure due to heating. For example, the term “unfolding” refers to the transition of from the liquid crystalline state to the molten globule state. In the molten globule state, tertiary and quaternary structure has been altered, relative to the native state of the protein, and at least some secondary structure remains intact. The term “unfolding” also encompasses loss of crystalline ordering of amino acid side-chains, secondary, tertiary or quaternary structure. The term “unfolding” also encompasses formation of a random coil.

“Folding” and “refolding,” and “renaturing” refer to the acquisition of the correct amino acid side-chain ordering, secondary, tertiary, or quaternary structure, of a protein or a nucleic acid, which affords the full chemical and biological function of the biomolecule.

The term “target molecule” encompasses peptides, proteins, nucleic acids, ions, and other receptors. The term encompasses both enzymes, and proteins which are not enzymes. The term encompasses monomeric and multimeric proteins. Multimeric proteins may be homomeric or heteromeric. The term encompasses nucleic acids comprising at least two nucleotides, such as oligonucleotides. Nucleic acids can be single-stranded, double-stranded, or triple-stranded. The term encompasses a nucleic acid which is a synthetic oligonucleotide, a portion of a recombinant DNA molecule, or a portion of chromosomal DNA. The term target molecule also encompasses portions of peptides, proteins, and other receptors which are capable of acquiring secondary, tertiary, or quaternary structure through folding, coiling or twisting. The target molecule may be substituted with substituents including, but not limited to, cofactors, coenzymes, prosthetic groups, lipids, oligosaccharides, or phosphate groups.

The terms “target molecule” and “receptor” are synonymous. Examples of target molecules are included, but not limited to those disclosed in Faisst, S. *et al.*, Nucleic Acids Research 20:3-26 (1992); Pimentel, E., Handbook of Growth Factors, Volumes I-III, CRC Press, (1994); Gilman, A. G. *et al.*, The Pharmacological Basis of Therapeutics, Pergamon Press (1990); Lewin, B., Genes V, Oxford University Press (1994); Roitt, I., Essential Immunology, Blackwell Scientific Publ. (1994); Shimizu, Y., Lymphocyte Adhesion Molecules, R G Landes (1993); Hyams, J. S. *et al.*, Microtubules, Wiley-Liss (1995); Montreuil, J. *et al.*, Glycoproteins, Elsevier (1995); Woolley, P., Lipases: Their Structure Biochemistry and Applications, Cambridge University Press (1994); Kurjan, J.,

- Signal Transduction: Prokaryotic and Simple Eukaryotic Systems, Academic Press (1993); Kreis, T., *et al.*, Guide Book to the Extra Cellular Matrix and Adhesion Proteins, Oxford University Press (1993); Schlesinger, M. J., Lipid Modifications of Proteins, CRC Press (1992); Conn, P. M., Receptors: Model Systems and Specific Receptors, Oxford University Press (1993); Lauffenberger, D. A. et al, Receptors. Models For Binding Trafficking and Signaling, Oxford University Press (1993); Webb, E. C., Enzyme Nomenclature, Academic Press (1992); Parker, M. G., Nuclear Hormone Receptors; Molecular Mechanisms, Cellular Functions Clinical Abnormalities, Academic Press Ltd. (1991); Woodgett, J. R., Protein Kinases, Oxford University Press (1995);
- 10 Balch, W. E. *et al.*, Methods in Enzymology, Vol. 257, Pt. C: "Small GTPases and Their Regulators: Proteins Involved in Transport," Academic Press (1995); The Chaperonins, Academic Press (1996); Pelech, L., Protein Kinase Circuitry in Cell Cycle Control, R G Landes (1996); Atkinson, Regulatory Proteins of the Complement System, Franklin Press (1992); Cooke, D. T. *et al.*, Transport and Receptor Proteins of Plant Membranes:
- 15 Molecular Structure and Function, Plenum Press (1992); Schumaker, V. N., Advances in Protein Chemistry: Lipoproteins, Apolipoproteins, and Lipases, Academic Press (1994); Brann, M., Molecular Biology of G-Protein-Coupled Receptors: Applications of Molecular Genetics to Pharmacology, Birkhauser (1992); Konig, W., Peptide and Protein Hormones: Structure, Regulations, Activity--A Reference Manual, VCH Publ. (1992);
- 20 Tuboi, S. *et al.*, Post-Translational Modification of Proteins, CRC Press (1992); Heilmeyer, L. M., Cellular Regulation by Protein Phosphorylation, Springer-Verlag (1991); Takada, Y., Integrin: The Biological Problem, CRC Press (1994); Ludlow, J. W., Tumor Suppressors: Involvement in Human Disease, Viral Protein Interactions, and Growth Regulation, R G Landes (1994); Schlesinger, M. J., Lipid Modification of
- 25 Proteins, CRC Press (1992); Nitsch, R. M., Alzheimer's Disease. Amyloid Precursor Proteins, Signal Transduction, and Neuronal Transplantation, New York Academy of Sciences (1993); Cochrane, C. G., *et al.*, Cellular and Molecular Mechanisms of Inflammation, Vol. 3: Signal Transduction in Inflammatory Cells, Part A, Academic Press (1992); Gupta, S. *et al.*, Mechanisms of Lymphocyte Activation and Immune
- 30 Regulation IV: Cellular Communications, Plenum Press (1992); Authi, K. S. *et al.*, Mechanisms of Platelet Activation and Control, Plenum Press (1994); Grunicke, H., Signal Transduction Mechanisms in Cancer, R G Landes (1995); and Latchman, D. S.,

- 22 -

Eukaryotic Transcription Factors, Academic Press (1995), all of which are incorporated herein by reference in their entirety.

The term “contacting a target molecule” refers broadly to placing the target molecule in solution with the molecule to be screened for binding or with the
5 condition(s) to be tested for stabilizing the target molecule. Less broadly, contacting refers to the turning, swirling, shaking or vibrating of a solution of the target molecule and the molecule to be screened for binding. More specifically, contacting refers to the mixing of the target molecule with the molecule to be tested for binding. Mixing can be accomplished, for example, by repeated uptake and discharge through a pipette tip, either
10 manually or using an automated pipetting device. Contacting can refer to the equilibration of binding between the target molecule and the molecule to be tested for binding. Contacting can occur in the container, infra, or before the target molecule and the molecule to be screened are placed in the container.

The target molecule may be contacted with a nucleic acid prior to being contacted
15 with the molecule to be screened for binding. The target molecule may be complexed with a peptide prior to being contacted with the molecule to be screened for binding. The target molecule may be phosphorylated or dephosphorylated prior to being contacted with the molecule to be screened for binding.

A carbohydrate moiety may be added to the target molecule before the target
20 molecule is contacted with the molecule to be screened for binding. Alternatively, a carbohydrate moiety may be removed from the target molecule before the target molecule is contacted with the molecule to be screened for binding.

The term “container” refers to any vessel or chamber in which the receptor and molecule to be tested for binding can be placed. The term “container” encompasses
25 reaction tubes (e.g., test tubes, microtubes, vials, etc.).

“Spectral emission,” “thermal change,” and “physical change” encompass the release of energy in the form of light or heat, the absorption of energy in the form or light or heat, changes in turbidity and changes in the polar properties of light. Specifically, the terms refer to fluorescent emission, fluorescent energy transfer, absorption of
30 ultraviolet or visible light, changes in the polarization properties of light, changes in the polarization properties of fluorescent emission, changes in the rate of change of fluorescence over time (i.e., fluorescence lifetime), changes in fluorescence anisotropy,

- 23 -

changes in fluorescence resonance energy transfer, changes in turbidity, and changes in enzyme activity. The terms may refer to fluorescence, including to fluorescence emission. Fluorescence emission can be intrinsic to a protein or can be due to a fluorescence reporter molecule. The use of fluorescence techniques to monitor protein
5 unfolding is well known to those of ordinary skill in the art. For example, see Eftink, M. R., Biophysical J. 66:482-501 (1994).

“Biochemical conditions” encompass any component of a physical, chemical, or biochemical reaction. Specifically, the term refers to conditions of temperature, pressure, protein concentration, pH, ionic strength, salt concentration, time, electric
10 current, potential difference, concentrations of cofactor, coenzyme, oxidizing agents, reducing agents, detergents, metal ion, ligands, or glycerol.

As used herein, the term “determining” generally refers to the analysis of a species, for example, quantitatively or qualitatively, and/or the detection of the presence or absence of the species. “Determining” may also refer to the analysis of an interaction
15 between two or more species, for example, quantitatively or qualitatively, and/or by detecting the presence or absence of the interaction.

U.S. Provisional Patent Application Serial No. 61/238,601, filed August 31, 2009, entitled “Kinase Sensors,” by Imperiali et al., is incorporated herein by reference.

The following examples are intended to illustrate certain embodiments of the
20 present invention, but do not exemplify the full scope of the invention.

EXAMPLES

Example 1

This example describes the synthesis and screening of Oxn derivatives. A
25 selection of substituted hydroxyquinoline derivatives related to a sulfonamide derivative (FIG. 1, complex 1), but bearing different acceptor groups at position 5 (FIG. 1, complexes 2-7) was prepared using previously described methods. These analogs were screened for fluorescence in the presence of excess Mg^{2+} and under buffered aqueous conditions. FIG. 1 lists fluorescence data for compounds 1-7. Notably, the excitation
30 and emission wavelengths were similar to those of 1; however, the quantum yields are poorer. Indeed, only the aldehyde-substituted chromophore 2 showed an improved

- 24 -

quantum yield. This derivative exhibited shorter λ_{em} , and the aldehyde group was readily oxidized.

Azide **8** (FIG. 2) was prepared using previously reported methods. Azide **8** showed low or essentially no fluorescence, and, without wishing to be bound by theory, this effect may be attributed to the quenching effect from the electron-rich azido group. In the presence of catalytic Cu(I) and ascorbic acid, **8** reacted readily at room temperature with 1-ethynylcyclohexene (**9a**) in DMF/4-methylpiperidine (8:2) to afford the cycloaddition product **10a** in essentially quantitative yield. Quinoline **10a** had a λ_{ex} of 371 nm and a λ_{em} of 522 nm. The fluorescence properties of the triazole-substituted quinolines were investigated for the products from the 1,3-dipolar cycloaddition reaction of **8** with 21 additional alkynes (**9b-v**) (FIG. 2).

The cycloaddition reactions were generally complete in 12 h at room temperature and were monitored by TLC and mass spectrometry. The formation of the fluorescent triazole compounds could be easily established upon exposure to a hand-held UV lamp ($\lambda_{ex} = 365$ nm). The fluorophores were then qualitatively compared in a 96-well plate (transilluminator; $\lambda_{ex} = 365$ nm) to identify promising compounds (FIG. 3) and were further subjected to quantitative analysis in a fluorescence plate reader (FIG. 8). The excitation and emission wavelengths of the triazole products (**10b-v**, $\lambda_{ex} = 360$ -375 nm, $\lambda_{em} = 510$ -530 nm) were improved compared to those for Sox (**1**, $\lambda_{ex} = 360$ nm, $\lambda_{em} = 485$ nm, $\Phi = 0.342$, $\epsilon_{355} = 8,247$ cm⁻¹ M⁻¹). Based on the preliminary screening, selected targets were then synthesized in larger quantities and the quantum yields of the corresponding hydroxyquinoline derivatives were determined. Compared to **10a** ($\Phi = 0.033$) a 3.5-fold improvement in quantum yield was obtained in the case of the bromide **10u** ($\lambda_{ex} = 375$ nm, $\lambda_{em} = 525$ nm, $\Phi = 0.111$, $\epsilon_{355} = 7,905$ cm⁻¹ M⁻¹). In view of the fluorescent properties of this derivative, it was chosen for use as a chelation-sensitive fluorophore to prepare probes for mitogen-activated protein kinase-activated protein kinase-2 (MK2), and sarcoma kinase (Src), used as models of Ser/Thr and Tyr kinases, respectively. For the purposes of comparison, the analogous fluorescent peptides containing the original Sox chromophore were also prepared as previously described.

Example 2

- 25 -

This example demonstrates the synthesis and evaluation of Clk-based peptidyl kinase substrates. The synthesis of the probes is outlined in FIG. 4. Diazotization of 5-amino-2-methylquinolin-8-ol (**12**, prepared from 8-hydroxyquinaldine using previously described methods) followed by treatment of the diazonium salt with NaN₃ gave the
5 corresponding azide **13** (66% yield). Protection of the phenolic hydroxyl group as a *tert*-butyldiphenylsilyl ether produced **14** (98% yield), which was then brominated under free radical conditions to afford the bromide **15** (30% yield). To avoid dibromination, the reaction was stopped after 20 min, thereby providing a mixture of the desired product (**15**) and the starting material (**14**), which was not separated and was used in the next step
10 without purification. Fmoc-based solid phase peptide synthesis (SPPS) was utilized to assemble the intact peptide that included an appropriately placed cysteine residue protected with monomethoxytrityl (Mmt), which is an acid-labile protecting group (FIG. 4). After selective on-resin sulfhydryl deprotection, the free thiol was alkylated with **15**. Then a 1,3-dipolar cycloaddition reaction with 1-bromo-4-ethynylbenzene in the
15 presence of catalytic Cu(I) gave the corresponding triazole-substituted peptide. Standard TFA cleavage from the resin and concomitant removal of all side-chain protecting groups revealed the desired chemosensor (> 95% yield).

FIG. 5 shows the substrate sequences of the Sox- and click (Clk)-based RDF probes for MK2 and Src kinases, as well as the fluorescence increases that were observed
20 with the corresponding phosphopeptides. The difference in fluorescence was determined by comparison of the fluorescence intensity at the maximum emission wavelength (485 nm for Sox and 525 nm for Clk) of phosphorylated and unphosphorylated peptides in the presence of Mg²⁺. The fluorescence increases of the click peptides are between 2- and 2.5-fold. The click-based RDF peptides exhibited larger fluorescence increases than the
25 Sox-based RDF peptides in the case of Src (FIG. 5, entries 3 and 4) while this trend is reversed in the case of MK2 (FIG. 5, entries 1 and 2). As an example, FIG. 6A shows a comparison between the fluorescence excitation and emission spectra of the synthetically-obtained phosphopeptide MK2(Sox) [**P1** (---)] and that from the analogous MK2(Clk) [**P2** (—)]. Samples were prepared in 50 mM HEPES (pH 7.4) and 150 mM
30 NaCl. Spectra were acquired at 25 °C and were baseline-corrected using a sample of the buffer solution. In the case of the Src sensors the result was the same. Neither species was fluorescent at pH 7.0 (50 mM HEPES, 150 mM NaCl) in the absence of the metal

- 26 -

ion. Upon addition of Mg^{2+} the fluorescence spectra of Mg^{2+} -bound **P1** and Mg^{2+} -bound **P2** exhibited emission maxima of 485 and 525 nm, respectively, indicating a red-shift of 40 nm. On the other hand, in the corresponding excitation spectra the Mg^{2+} -bound **P1** reached a maximum at 360 nm and Mg^{2+} -bound **P2** emission peaked at 375 nm, representing a bathochromic shift of 15 nm.

Example 3

This example demonstrates evaluation of Clk-based substrates in enzymatic assays. Following established protocols, Sox- and Clk-based substrates (FIG. 5, entries 1 and 2, respectively) were subjected to MK2 under identical conditions and then the overall turnover of each substrate was compared. FIG. 6B shows the percentage of turnover of the Clk-based (■, FIG. 5, entry 2) or Sox-based (□, FIG. 5, entry 1) substrate with MK2 after 10 min. Assays were performed in 20 mM HEPES (pH 7.4), 10 mM $MgCl_2$, 0.1 mM EGTA, 0.01% Brij 35, 0.1 mg/mL BSA, 1 mM DTT, 1 mM ATP, 5 μ M substrate and 10 ng MK2 at 30 °C. Plotted values indicate the mean $\pm$ s.e.m. for triplicate measurements. As shown in FIG. 6B, MK2 phosphorylated the Clk-substrate just as efficiently as the Sox substrate indicating that the size of Clk chromophore does not adversely influence reaction kinetics..

In conclusion, the synthesis, peptide incorporation, and characterization of new phosphorylation chemosensors that contain 1,3-triazole-substituted 8-hydroxyquinolines and exhibit improved fluorescence properties compared to Sox was achieved. This modification results in significant red-shifts in the excitation (15 nm) and emission maxima (40 nm) of the chromophore when complexed to Mg^{2+} . Moreover, the chromophore does not inhibit the ability of MK2 to recognize and phosphorylate the Clk probe.

Example 4

This example provides the materials and methods information for Example 1-3 above.

General information. All solvents and reagents were obtained commercially and used without further purification, unless otherwise noted. N α -Fmoc-protected amino acids [Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Cyc(Mmt)-OH, Fmoc-Glu(OtBu)-OH,

- 27 -

Fmoc-Gln(Trt)-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(PO(OBn)OH)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Tyr(PO(OBn)OH)-OH]§ were purchased from Novabiochem. Whenever anhydrous and/or degassed CH₂Cl₂ was necessary it was distilled from calcium hydride under an argon atmosphere. Analytical TLC was performed on silica gel 60 F₂₅₄ precoated plates (EMD Chemicals Inc.) and visualized by UV. Flash column chromatography was performed as previously described using forced flow of the indicated solvent on AdTech Flash Silica Gel (32-60 micron packing, 60 Angstrom pore diameter, Adedge Technologies). Organic solutions were concentrated *in vacuo* by rotary evaporation at ~10 Torr (house vacuum) at 25-40 °C, then at ~0.5 Torr (vacuum pump), unless otherwise indicated. Peptides were purified *via* preparative reverse-phase C18 HPLC employing a gradient of solvents A (H₂O with 0.1% v/v TFA) and B (CH₃CN with 0.1% v/v TFA). Compounds were characterized by ¹H, ¹³C NMR and mass spectrometry. Peptide purity was determined by analytical reverse-phase HPLC.

Abbreviations. AIBN: Azobisisobutyronitrile; ATP: adenosine triphosphate; Bn: benzyl; tBu: *t*-butyl; Boc: *t*butoxycarbonyl; DIEA: diisopropylethylamine; BSA: bovine serum albumin; DMF: *N,N*-dimethylformamide; DMSO: dimethyl sulfoxide; DTT: dithiothreitol; EDTA: ethylenediaminetetraacetic acid; EGTA: glycol-bis(2-aminoethylether)-*N,N,N',N'*-tetraacetic acid; ESI-MS: Electrospray Ionization Mass Spectrometry; Fmoc: 9-fluorenylmethoxycarbonyl; FPR: fluorescence plate reader; HEPES: 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid; HOAt: 7-aza-1-hydroxybenzotriazole; HOBt: 1-hydroxybenzotriazole; HPLC: high performance liquid chromatography; HRMS: high resolution mass spectrometry; MK2: mitogen-activated protein kinase-activated protein kinase-2; Mmt: 4-methoxytrityl; NBS: *N*-bromosuccinimide; NMR: nuclear magnetic resonance; Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; PyAOP: (7-azabenzotriazol-1-yl-oxy)tripyrrolidinophosphonium hexafluorophosphate; PyBOP: Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate; RDF: recognition-domain focused; Sox-Br: 2-bromomethyl-8-*t*-butyldiphenylsilyloxy-5-(*N,N*-dimethyl)sulfonamidoquinoline; SPPS: solid-phase peptide synthesis; Src: sarcoma kinase; TFA: trifluoroacetic acid; TIS: triisopropylsilane; TLC: thin-layer chromatography; TNBS: 2,4,6-trinitrobenzene sulfonic acid; Trt: trityl; UV: Ultra-Violet.

- 28 -

Instrumentation. NMR: ^1H and ^{13}C NMR spectra were recorded on a Bruker 400 MHz Avance spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) and referenced to CDCl_3 (7.26 ppm for ^1H and 77.0 ppm for ^{13}C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are abbreviated as singlet (s),
5 doublet (d), doublet of doublets (dd), triplet (t) and multiplet (m). HPLC: HPLC was carried out on Waters Prep LC 4000 System or Waters Delta 600 System equipped with Waters 2487 dual wavelength absorbance detectors. Columns used: C18 analytical (flow rate = 1 mL/min), Beckman Ultrasphere ODS, 5 micron, 150 x 4.6 mm; C18 preparatory (flow rate = 15 mL/min), YMC-Pack Pro, 5 micron, 250 x 20 mm. ESI-MS: Applied
10 Biosystems Mariner mass spectrometer. MALDI-TOF MS: PerSeptive Biosystems Voyager MALDI-TOF instrument. HRMS: Provided by the Department of Chemistry Instrumentation Facility (DCIF), MIT. UV-Vis Spectrophotometer: Shimadzu UV-2401PC. Fluorometer: Fluoromax 3 from Jobin Yvon. Cuvette: Starna Cells (16.100F-Q-10) 100 microliter sub-micro cuvette, 1 cm path length. Fluorescence Plate Reader:
15 HTS 7000 Bio Assay Reader from Perkin Elmer or SpectraMax GeminiXS Dual Scanning Microplate Spectrofluorometer from Molecular Devices. Plate: Corning assay plate, 96-well, half area, no lid, flat bottom, non-binding surface, nonsterile, white polystyrene.

Synthesis of the Triazolyl Derivatives 10a-v. 5-Azido-8-hydroxy-2-methylquinoline (13, 50 mg, 0.26 mmol) and the corresponding alkyne (9a-v) (0.26
20 mmol) were suspended in a 8:2 mixture of DMF/4-methylpiperidine (2 mL). Ascorbic acid (7.1 mg, 0.04 mmol) and copper iodide (2.5 mg, 0.01 mmol) were added suspended in a 8:2 mixture of dimethylformamide/4-methylpiperidine (1 mL) and the heterogeneous mixture was stirred vigorously overnight in the dark at room temperature.
25 TLC analysis indicated complete consumption of the reactants in 12 h. The mixture was dissolved in ethyl acetate (40 mL), was washed with H_2O (5 mL), brine (5 mL), dried over Na_2SO_4 , and evaporated to yield the corresponding triazolyl derivatives 10a-v.

Peptide Synthesis. All peptides were synthesized using the standard Fmoc-based amino acid protection chemistry. Peptides were synthesized on Fmoc-PAL-PEG-
30 PS resin (Applied Biosystems, 0.19 mmol/g) using on resin alkylation. The resin was swelled in CH_2Cl_2 (5 min.) and then DMF (5 min) prior to synthesis. All the amino acids were coupled according to the following procedure: Fmoc deprotection (20% 4-

- 29 -

methylpiperidine in DMF, 3 x 5 min), rinsing step (DMF, 5 x), coupling step (amino acid/PyBOP/HOBt/DIEA, 6:6:6:6, 0.15 M in DMF, 30-45 min), rinsing step (DMF, 5 x; CH₂Cl₂, 5 x). The coupling was repeated if necessary as determined by the TNBS test. At the end of the synthesis, the Fmoc group was removed with 20% 4-methylpiperidine in DMF (3 x 5 min.) and the resin was rinsed with DMF (5 x). The resin-attached free amines were capped by exposure to Ac₂O (20 equiv.) and pyridine (20 equiv.) in DMF for 30 min. The resin was rinsed with DMF (5 x), CH₂Cl₂ (5 x) and subjected to 20% 4-methylpiperidine in DMF (3 x 5 min.). The resin was finally washed with DMF, CH₂Cl₂, MeOH (5 x each) and dried under vacuum.

10 **On-resin Alkylation of Peptides with 15.** Resin-attached peptides (50 mg, 0.0095 mmol, 1 equiv.) incorporating Cys(Mmt) were swelled in CH₂Cl₂, then DMF. The Mmt protecting group was removed from the resin-bound peptide by bubbling N₂ through a solution of 1% TFA, 5% TIS in CH₂Cl₂ (4 x 20 min). The resin was washed with CH₂Cl₂ (5 x) and DMF (5 x). Anhydrous DMF (200 microliters) was added to the resin followed by freshly distilled tetramethylguanidine (5.96 µL, 0.0475 mmol, 5 equiv.). The mixture was incubated for 2-3 min. **15** (17 mg, 0.0285 mmol, 3 equiv.) was dissolved in anhydrous DMF (150 microliters) and added to the resin. After ca. 12 hours of reaction time, the excess reagents were drained and the resin washed with DMF, CH₂Cl₂, MeOH, CH₂Cl₂ (5 x).

20 **On-resin Click Chemistry of Peptides with 9u.** Resin-attached peptides (50 mg, 0.0095 mmol, 1 equiv.) incorporating 5-Azido-8-Hydroxyquinoline were swelled in CH₂Cl₂, then DMF (5 min). A mixture of 1-bromo-4-ethynylbenzene (**9u**; 34.4 mg, 0.19 mmol), ascorbic acid (0.75 mg, 0.0043 mmol) and copper iodide (0.27 mg, 0.0014 mmol) was added to the resin suspended in a 8:2 mixture of DMF/4-methylpiperidine (1.5 mL). After ca. 12 hours of reaction time, the excess reagents were drained and the resin washed with DMF, CH₂Cl₂, MeOH, CH₂Cl₂ (5x). The resin cleavage and protecting group removal was achieved by exposing the resin-bound peptides to TFA/H₂O/TIS (95:2.5:2.5% v/v). The resulting solution was concentrated under a stream of N₂ and precipitated by addition of cold Et₂O. The pellet was triturated with cold Et₂O, redissolved in water, filtered and lyophilized. The peptides were purified by preparative reverse-phase HPLC using UV detection at 228 nm (amide bond absorption)

- 30 -

and 316 nm (8-hydroxyquinoline absorption). Only fractions showing a single peak of correct mass by analytical HPLC were used in further experiments.

Synthesis and Characterization of Oxine derivatives. Compounds **1**, **2**, **3**, **4**, **6**, and **7** were prepared by previously described methods. Characterization of each compound was consistent with literature.

5-Carbaldehyde-8-Hydroxy-2-methylquinoline (2). Yield: 64 %, ¹H NMR (500 MHz, CDCl₃) δ ppm: 2.75 (s, 3H), 7.24 (d, *J* = 8 Hz, 1H), 7.51 (d, *J* = 8 Hz, 1H), 7.90 (d, *J* = 8 Hz, 1H), 9.51 (d, *J* = 8 Hz, 1H), 10.01 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ ppm: 24.6, 108.8, 123.6, 124.6, 125.4, 134.6, 137.4, 139.0, 157.4, 158.0, 191.6. HRMS (ESI): calc'd for C₁₁H₉NO₂ [M + H]⁺: 188.0706, found: 188.0711.

5-Carbonitrile-8-Hydroxy-2-methylquinoline (3). Yield: 79%, ¹H NMR (500 MHz, CDCl₃) δ ppm: 2.77 (s, 3H), 7.15 (d, *J* = 8.5 Hz, 1H), 7.52 (d, *J* = 8.5 Hz, 1H), 7.83 (d, *J* = 8.5 Hz, 1H), 8.37 (d, *J* = 8.5 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ ppm: 23.7, 27.6, 106.3, 121.1, 124.5, 125.2, 134.0, 137.6, 157.0, 158.9. HRMS (ESI): calc'd for C₁₁H₈N₂O [M + H]⁺: 185.0709, found: 185.0704.

1-(8-Hydroxy-2-methylquinolin-5-yl)ethanone (4). Yield: 66%, ¹H NMR (500 MHz, CDCl₃) δ ppm: 2.70 (s, 3H), 2.75 (s, 3H), 7.13 (d, *J* = 8 Hz, 1H), 7.46 (d, *J* = 9 Hz, 1H), 8.10 (d, *J* = 8 Hz, 1H), 9.45 (d, *J* = 9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ ppm: 24.5, 28.6, 108.3, 124.5, 125.0, 125.2, 133.0, 136.5, 156.0, 157.2, 199.1. HRMS (ESI): calc'd for C₁₂H₁₁NO₂ [M + H]⁺: 202.0863, found: 202.0856.

8-Hydroxy-2-methylquinoline-5-Carbonyl chloride (5). Compound **5** was prepared with 2-chloroacetyl chloride following the same procedure used to obtain **4**. Yield: 71%, ¹H NMR (500 MHz, CDCl₃) δ ppm: 2.76 (s, 3H), 4.78 (s, 2H), 7.15 (d, *J* = 8 Hz, 1H), 7.51 (d, *J* = 9 Hz, 1H), 8.06 (d, *J* = 8 Hz, 1H), 9.39 (d, *J* = 9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ ppm: 24.6, 46.9, 108.3, 121.3, 125.4, 125.5, 132.7, 135.9, 157.0, 157.7, 191.4. HRMS (ESI): calc'd for C₁₂H₁₀ClNO₂ [M + H]⁺: 236.0473, found: 236.0479.

8-Hydroxy-5-(4-cyclohexenyl-1H-1,2,3-triazol-1-yl)quinoline (10a). 1-Ethynyl-1-cyclohexene (**9a**) was used as the starting material. ¹H NMR (500 MHz, CD₃OD) δ ppm: 1.71-1.79 (m, 2H), 1.82-1.86 (m, 2H), 2.26-2.28 (m, 2H), 2.48-2.49 (m, 2H), 6.62 (m, 1H), 7.36 (d, *J* = 8.5 Hz, 1H), 7.79 (d, *J* = 8.5 Hz, 1H), 7.83 (dd, *J* = 4 and 8.5 Hz, 1H), 8.22 (s, 1H), 8.39 (d, *J* = 8.5 Hz, 1H), 9.02 (d, *J* = 4 Hz, 1H). ¹³C NMR (125 MHz, CD₃OD) δ ppm: 23.4, 23.7, 26.4, 27.5, 113.1, 123.7, 124.7, 126.0, 126.6, 127.0, 127.7,

- 31 -

128.3, 136.0, 137.4, 148.6, 150.9, 154.4. HRMS (ESI): calc'd for $C_{17}H_{16}N_4O$ $[M + H]^+$: 293.1397, found: 293.1394.

8-Hydroxy-5-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline (10b). Ethynylbenzene (**9b**) was used as the starting material. ^1H NMR (500 MHz, CD_3OD) δ ppm: 7.30 (d, $J = 8.5$ Hz, 1H), 7.41 (dd, $J = 1.5$ and 7.5 Hz, 1H), 7.49 (t, $J = 7.5$ Hz, 2H), 7.70 (dd, $J = 4.5$ and 9.5 Hz, 1H), 7.77 (d, $J = 8.5$ Hz, 1H), 7.96 (dd, $J = 1.5$ and 8.5 Hz, 2H), 8.21 (d, $J = 8.5$ Hz, 1H), 8.74 (s, 1H), 8.97 (dd, $J = 1.5$ and 4.5 Hz, 2H). ^{13}C NMR (125 MHz, CD_3OD) δ ppm: 111.7, 127.0, 127.1, 129.8, 130.2, 131.5, 134.3, 138.4, 149.2, 149.9, 155.9. HRMS (ESI): calc'd for $C_{17}H_{12}N_4O$ $[M + H]^+$: 289.1084, found: 289.1076.

10 **8-Hydroxy-5-(4-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)quinoline (10c)**
1-Ethynyl-3,5-bis(trifluoromethyl)benzene (**9c**) was used as the starting material. ^1H NMR (500 MHz, CD_3OD) δ ppm: 7.38 (d, $J = 8.5$ Hz, 1H), 7.84 (dd, $J = 4.5$ and 8.5 Hz, 1H), 7.87 (d, $J = 8.5$ Hz, 1H), 7.99 (s, 1H), 8.52 (dd, $J = 1.5$ and 8.5 Hz, 1H), 8.57 (s, 1H), 9.03 (dd, $J = 1.5$ and 4.5 Hz, 1H), 9.07 (s, 1H). ^{13}C NMR (125 MHz, CD_3OD) δ ppm: 113.2, 122.8, 123.8, 124.6, 124.8, 125.7, 125.9, 126.6, 127.0, 127.9, 133.6, 134.4, 146.4, 148.6, 154.5. HRMS (ESI): calc'd for $C_{19}H_{10}F_6N_4O$ $[M + H]^+$: 425.0832, found: 425.0836.

8-Hydroxy-5-(4-(3-chlorophenyl)-1H-1,2,3-triazol-1-yl)quinoline (10d). 1-Chloro-3-ethynylbenzene (**9d**) was used as the starting material. ^1H NMR (500 MHz, CD_3OD) δ ppm: 7.34 (d, $J = 8.5$ Hz, 1H), 7.41 (d, $J = 8$ Hz, 1H), 7.48 (t, $J = 8$ Hz, 1H), 7.77 (dd, $J = 4.5$ and 8.5 Hz, 1H), 7.81 (dd, $J = 8$ Hz, 1H), 7.90 (d, $J = 8$ Hz, 1H), 8.01 (s, 1H), 8.32 (dd, $J = 1.5$ and 8.5 Hz, 1H), 8.82 (s, 1H), 9.01 (dd, $J = 1.5$ and 4.5 Hz, 1H). ^{13}C NMR (125 MHz, CD_3OD) δ ppm: 112.3, 124.7, 125.2, 125.6, 125.7, 126.4, 126.8, 127.4, 129.6, 131.8, 133.6, 135.6, 136.2, 137.4, 147.9, 149.4, 155.4. HRMS (ESI): calc'd for $C_{17}H_{11}ClN_4O$ $[M + H]^+$: 323.0621, found: 323.0625.

8-Hydroxy-5-(4-p-tolyl-1H-1,2,3-triazol-1-yl)quinoline (10i)
1-Ethynyl-4-methylbenzene (**9i**) was used as the starting material. ^1H NMR (500 MHz, CD_3OD) δ ppm: 2.40 (s, 3H), 7.31 (d, $J = 8.5$ Hz, 1H), 7.41 (d, $J = 8.5$ Hz, 1H), 7.83-7.88 (m, 2H), 7.84 (d, $J = 8$ Hz, 1H), 7.88 (d, $J = 8$ Hz, 1H), 8.50 (d, $J = 8.5$ Hz, 1H), 8.72 (s, 1H), 9.04 (dd, $J = 1.5$ and 4.5 Hz, 1H). ^{13}C NMR (125 MHz, CD_3OD) δ ppm: 21.4, 113.4, 124.6, 124.7, 126.0, 126.7, 126.9, 128.0, 128.6, 130.8, 138.0, 140.0, 148.4,

- 32 -

149.5, 154.2. HRMS (ESI): calc'd for $C_{17}H_{11}ClN_4O$ $[M + H]^+$: 323.0694, found: 323.0702.

8-Hydroxy-5-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)quinoline (10u)

1-Bromo-4-ethynylbenzene (**9u**) was used as the starting material. ^1H NMR (500 MHz, $CDCl_3$) δ ppm: 7.28 (d, $J = 8$ Hz, 1H), 7.56 (dd, $J = 4$ and 8.5 Hz, 1H), 7.60-7.64 (m, 2H), 7.61 (d, $J = 8$ Hz, 1H), 7.81-7.83 (m, 1H), 7.82 (d, $J = 8.5$ Hz, 1H), 8.11 (s, 1H), 8.16 (d, $J = 8.5$ Hz, 1H), 8.90 (d, $J = 3.5$ Hz, 1H). ^{13}C NMR (125 MHz, $CDCl_3$) δ ppm: 108.9, 122.2, 122.5, 123.5, 124.2, 124.3, 125.1, 127.4, 129.0, 132.1, 132.2, 137.7, 146.9, 148.9, 153.9. HRMS (ESI): calc'd for $C_{17}H_{11}BrN_4O$ $[M + H]^+$: 367.0189, found: 367.0187.

5-Azido-8-hydroxy-2-methylquinoline (13). 5-Amino-8-hydroxy-2-methylquinoline (**12**; 723 mg, 4.2 mmol) was dissolved in a solution of concentrated hydrochloric acid (0.4 mL) and water (5 mL), cooled to -3 °C in a salt-ice bath, stirred for 10 min, then treated dropwise with a cold solution of sodium nitrite (0.50 g, 7.2 mmol) in water (5 mL). The mixture was stirred for 20 min, then treated dropwise with sodium azide (0.60 g, 9.2 mmol) in water (40 mL), stirred at 0 °C for a further 1.5 h, then allowed to warm to room temperature over 24 h in the dark. Isolation by extraction with diethyl ether gave a dark brown solid, which was recrystallized from light petroleum to yield **13** as light brown crystals (554 mg, 66%). ^1H NMR (500 MHz, CD_3OD) δ ppm: 3.31 (s, 3H), 7.06 (d, $J = 8.5$ Hz, 1H), 7.15 (d, $J = 8.5$ Hz, 1H), 7.36 (d, $J = 8.5$ Hz, 1H), 8.21 (d, $J = 8.5$ Hz, 1H). ^{13}C NMR (125 MHz, CD_3OD) δ ppm: 24.9, 111.8, 115.6, 121.6, 123.7, 127.9, 132.6, 139.6, 151.1, 159.7. HRMS (ESI): calcd for $C_{10}H_8N_4O$ $[M + H]^+$: 201.0771, found: 201.0773.

5-Azido-8-tert-butyldiphenylsilyloxy-2-methylquinoline (14). A 100-mL flask was successively loaded with dry DMF (10 mL), **13** (200 mg, 1 mmol), imidazole (68.08 mg, 1 mmol), and *tert*-butyldiphenylsilyl chloride (302 mg, 1.1 mmol). The solution was stirred at room temperature for 10 h, diluted with ethyl acetate (500 mL), washed with aqueous HCl (0.1 M, 50 mL), brine (100 mL), water (100 mL), dried over Na_2SO_4 and evaporated under reduced pressure to afford 8.41 g (96%) of protected product as a colorless oil (428 mg, 98%). ^1H NMR (500 MHz, $CDCl_3$) δ ppm: 1.19 (s, 9H), 2.33 (s, 3H), 6.98 (d, $J = 8.5$ Hz, 1H), 7.06 (d, $J = 8.5$ Hz, 1H), 7.10 (d, $J = 8.5$ Hz, 1H), 7.38-7.26 (m, 6H),

- 33 -

7.81-7.79 (m, 4H), 8.11 (d, $J = 8.5$ Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ ppm: 20.1, 24.3, 26.8, 113.5, 116.7, 120.6, 121.8, 127.3, 128.4, 129.2, 130.6, 134.3, 135.1, 140.9, 148.9, 157.9. HRMS (ESI): calc'd for $\text{C}_{26}\text{H}_{26}\text{N}_4\text{OSi}$ $[\text{M} + \text{H}]^+$: 438.1876, found: 438.1879.

- 5 **5-Azido-2-bromomethyl-8-tert-butyl-diphenylsilyloxyquinoline (15).** NBS (165.5 mg, 0.93 mmol) and AIBN (152.7 mg, 0.93 mmol) were added to a solution of **14** (371 mg, 0.85 mmol) in CCl_4 (4.5 mL), and the mixture was refluxed 20 min and evaporated to dryness. The residue was dissolved in CH_2Cl_2 (20 mL), the solution was washed with H_2O (5 mL) and brine (5 mL), dried over Na_2SO_4 , and evaporated. The residue was
- 10 purified by flash chromatography, using 20-50% gradient of EtOAc in hexane as eluent, to yield the unresolved (3:1) mixture of **14** and **15** (131.6 mg, 30%). ^1H NMR (500 MHz, CDCl_3) δ ppm: 1.16 (s, 9H), 4.24 (s, 2H), 6.97 (d, $J = 8.5$ Hz, 1H), 7.03 (d, $J = 8.5$ Hz, 1H), 7.09 (d, $J = 8.5$ Hz, 1H), 7.26-7.43 (m, 6H), 7.76-7.78 (m, 4H), 8.24 (d, $J = 8.5$ Hz, 1H). HRMS (ESI): calc'd for $\text{C}_{26}\text{H}_{25}\text{BrN}_4\text{OSi}$ $[\text{M} + \text{H}]^+$: 517.1054, found:
- 15 517.1050.

Stock solutions. Due to the affinity of the phosphorylated peptides for selected transition metal ions, by analogy with previously reported peptides, only reagents of the highest purity and lowest metal content were used to avoid the need to remove metal ion impurities after preparation.

- 20 1. Stock solutions of the peptides were prepared in doubly deionized water and concentrations were determined by UV-Vis (based on the determined extinction coefficient of the fluorophore moiety, either **1** (Sox), $\epsilon_{355} = 8247 \text{ M}^{-1} \text{ cm}^{-1}$ or **10u** (Clk), $\epsilon_{360} = 7905 \text{ M}^{-1} \text{ cm}^{-1}$ in 0.1 M NaOH with 1 mM Na_2EDTA). An average of the values from three separate solutions, each prepared using a different volume of the stock
- 25 solution, was read on UV-Vis spectrophotometer. Purified peptide stock solutions could be stored at 4 °C for at least 6 months or -20 °C for longer periods.
2. 500 mM HEPES (SigmaUltra) was prepared and adjusted to pH 7.4 with NaOH (99.998+%, Aldrich) solution.
3. 10 mM DTT (Biotechnology grade, Mallinckrodt) was prepared in degassed ultrapure
- 30 water and stored in aliquots at -80 °C.
4. 500 mM EGTA (SigmaUltra) was prepared in 2 M NaOH and stored at 4 °C.

- 34 -

5. A magnesium chloride stock solution of 2.66 M was prepared using Alfa Aesar Puratronic grade salts. Most commercially available salts contain Zn^{2+} as significant impurities and should not be used due to the high affinity of the phosphorylated peptides for Zn^{2+} . The Mg^{2+} concentration was determined by titration with a standardized
5 solution of EDTA (Aldrich) in the presence of an Eriochrome Black T (Aldrich) as described previously.

6. 500 mM HEPES (SigmaUltra) was prepared and adjusted to pH 7.4 with NaOH (99.998+%, Aldrich) solution.

7. 20 mg/mL BSA (Heat Shock Fraction V, Roche) was prepared in ultrapure water,
10 filtered through a 0.45 micron syringe filter to remove particulates and stored at 4 °C.

8. 100 mM ATP (Disodium salt, Low Metals Grade, Calbiochem) was prepared in ultrapure water. The solution was stored in aliquots at -80 °C.

Fluorescence experiments.

a. Fluorescence analysis of 8-hydroxyquinoline click products. A 96-well microtier plate
15 was used in the experiments for preliminary examination of fluorescence properties. The overall volume in each well was 200 microliters. Individual reactions contained the crude product from the click chemistry reaction (10 micromolar dissolved in DMSO), MgCl_2 (10 mM), NaCl (150 mM) and HEPES (50 mM) at 25 °C (pH 7.4). The fluorescence spectra were recorded with fixed excitation at 370 nm and emission at 525
20 nm. The excitation and emission wavelengths for each fluorophore are summarized in FIG. 8. Based on the preliminary screening, selected products were then synthesized in larger quantities and the quantum yields of the corresponding hydroxyquinoline derivatives were determined.

b. Extinction coefficient determination. Extinction coefficients of **1** and **10u** were
25 measured in 50 mM HEPES (pH 7.0), 150 mM NaCl. The ϵ_{max} values were determined by plotting absorbance at 360 nm versus concentration for four chromophore solutions with concentrations between 20 and 60 micromolar and including 1 mM MgCl_2 .

c. Quantum yield determination. The quantum yield (Φ) was determined in 20 mM HEPES (pH 7.4). Quinine sulphate dihydrate (QS, Fluka, puriss. for fluorescence) in 0.1
30 M H_2SO_4 was used as a standard ($\Phi = 0.55$). A 4 micromolar solution of the corresponding oxine derivative with 50 mM MgCl_2 was compared to a 4 micromolar solution of quinine sulfate to assure that the absorbance (A_{360}) is less than 0.05 at

- 35 -

identical excitation wavelengths. The following equation was used to calculate the quantum yield:

$$\Phi = IA_{QS} \Phi_{QS} / AI_{QS}$$

5

where $A = A_{360}$ and I = integrated fluorescence intensity ($\lambda_{ex} = 360$ nm). The calculated Φ assumes that the refractive index of 0.1 M H_2SO_4 is identical to that of 20 mM HEPES (pH 7.4). The error associated with the Φ of quinine sulfate is at least 10%, the error in Φ is no less than 10%.

10 *d. Spectral comparison of phosphorylated and unphosphorylated peptides.* The fluorescence spectra of 10 micromolar phosphorylated (black line) and unphosphorylated (red line) peptides in 20 mM HEPES (pH 7.4) and 10 mM $MgCl_2$ were recorded in the fluorometer (slit widths: $E_m = 5$ nm, $E_x = 5$ nm; $\lambda_{ex} = 360$ nm, $\lambda_{em} = 380$ -650 nm) in a quartz microcuvette (120 microliters) (FIG. 9).

15 *e. Enzyme Experiments with MK2 and C-Sox- or C-Clk-based Substrates.* Recombinant MK2 (Upstate, appropriately diluted with 20 mM HEPES [pH 7.4], 1 mM DTT, 0.1% Brij-35, and 1 mg/mL BSA) was added to initiate each reaction. The assays were performed in the fluorometer (slit widths: $E_m = 5$ nm, $E_x = 5$ nm; $\lambda_{ex} = 360$ nm, $\lambda_{em} = 485$ nm) using a quartz microcuvette (120 μ L) at 30 °C for 10 min. Standard assay
20 conditions were as follows: 20 mM HEPES (pH 7.4), 10 mM $MgCl_2$, 1 mM ATP, 1 mM DTT, 0.1 mM EGTA, 0.01% Brij-35, 0.1 mg/mL BSA, 1 ng MK2. The percent turnover (% TO) for C-Sox- and C-Clk-based peptides was then calculated from fluorescence intensity after 10 min of reaction time and using previously described protocols.

While several embodiments of the present invention have been described and
25 illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials,
30 and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present invention is/are used.

- 36 -

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and
5 equivalents thereto, the invention may be practiced otherwise than as specifically described and claimed. The present invention is directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not
10 mutually inconsistent, is included within the scope of the present invention.

All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.

The indefinite articles “a” and “an,” as used herein in the specification and in the
15 claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”

The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases.

20 Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as
25 “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

As used herein in the specification and in the claims, “or” should be understood
30 to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and,

- 37 -

optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives
5 (i.e. “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of”, when used in the claims, shall have its ordinary meaning as used in the field of patent law.

As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one
10 element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least
15 one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally
20 including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

It should also be understood that, unless clearly indicated to the contrary, in any
25 methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,”
30 “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases,

- 38 -


respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

What is claimed is:

- 39 -

CLAIMS

1. A composition, comprising:
a compound having a structure as in formula (I):




- 5 where R_1 and R_2 are each independently hydrogen or aryl, or where R_1 and R_2 together with the carbon atoms of the triazole ring to which they are connected form a ring;

R_3 is independently hydrogen, alkyl, aryl, halo, or hydroxyl, amino, thiol, sulfonic acid, sulfonamide or a substituted derivative thereof, wherein R_3 can substitute
10 any open valence of any ring within structure (I);

m is 1, 2, 3, 4, or 5; and

R_4 is hydroxyl, amino, thiol, or a substituted derivative thereof.

2. A composition, comprising:
15 a compound having a structure as in formula (II):



where R_1 and R_2 are each independently hydrogen or aryl, or where R_1 and R_2 together with the carbon atoms of the triazole ring to which they are connected form a ring; and

- 20 R_3 comprises:


- i) a species capable of fluorescing, and
- ii) a protein kinase substrate or at least one amino acid.

3. A composition as in any preceding claim, wherein R_1 is aryl and R_2 is hydrogen.

- 40 -

4. A composition as in any preceding claim, wherein R_3 comprises a protein kinase substrate.

5. A composition as in any preceding claim, wherein the compound comprises the following structure,




wherein “~” comprises a protein kinase substrate or at least one amino acid.

6. A method, comprising:
10 determining phosphorylation of a protein kinase substrate using fluorescence of a composition, wherein the composition has a fluorescence emission maximum greater than 490 nm.

7. A method, comprising:
15 determining phosphorylation of a protein kinase substrate using fluorescence of a composition, wherein the composition has a fluorescence extinction coefficient greater than $1000 \text{ M}^{-1} \text{ cm}^{-1}$ at a fluorescence emission wavelength greater than 490 nm.

8. A method, comprising:
20 determining phosphorylation of a protein kinase substrate using fluorescence of a composition of formula (II):




where R_1 and R_2 are each independently hydrogen or aryl, or where R_1 and R_2 together with the carbon atoms which they substitute form a ring; and

- 41 -

R₃ comprises:


- i) a species capable of fluorescing, and
- ii) a protein kinase substrate or at least one amino acid.

- 5 9. A method as in any preceding claim, wherein the compound comprises the following structure,



wherein “~” comprises a protein kinase substrate or at least one amino acid.

1/19



Complex	R ¹	R ²	λ_{ex} (nm)	λ_{em} (nm)	$\Phi^{a,b}$
1 ^c	SO ₂ N(CH ₃) ₂	CH ₃	360	485	0.342
2	CHO	CH ₃	373	460	0.597
3	CN	CH ₃	362	485	0.276
4	COCH ₃	CH ₃	370	465	0.168
5	COCH ₂ Cl	CH ₃	373	460	0.034
6	CO ₂ H	CH ₃	362	505	0.004
7	CO-Ph	H	375	485	0.002

^a Spectra were acquired in 150 mM NaCl, 50 mM HEPES (pH 7.4), 25°C with 10 μ M 1-7 and 10 mM MgCl₂. ^b Excitation of all species is provided at λ_{max} (355-425 nm). Quantum yields were calculated with reference to a quinine sulphate standard (in 0.05 M H₂SO₄). ^c Extinction coefficient: $\epsilon_{355}=8,247$ cm⁻¹ M⁻¹.

Fig. 1

2/19




Fig. 2

3/19




Fig. 3




Fig. 4

4/19

Entry	Target kinase	Location of the chromophore ^a	Peptide Sequence ^b	Fold Fluorescence Increase ^c	
1	MK2	C	Ac-AHL <u>QRQLS</u> *I-C(Sox)-HH-CONH ₂	4.4±0.2	SEQ ID NO:1
2	MK2	C	Ac-AHL <u>QRQLS</u> *I-C(Clk)-HH-CONH ₂	2.1±0.3	SEQ ID NO:2
3	Src	N	Ac-AEE-C(Sox)-IY* <u>GEFE</u> AKKKK-CONH ₂	2.0±0.1	SEQ ID NO:3
4	Src	N	Ac-AEE-C(Clk)-IY* <u>GEFE</u> AKKKK-CONH ₂	2.4±0.2	SEQ ID NO:4

^aLocation determined in reference to the chromophore. C denotes C-terminus and N stands for N-terminus. ^bAsterisk (*) denotes the residue that is phosphorylated. In cases where it has been determined, residues important in kinase recognition are underlined. ^cMeasured in triplicate as a quotient of fluorescence intensity at 485 nm (for Sox peptides) or 525 nm (for Clk peptides) of phosphopeptide and substrate in 20 mM HEPES (pH 7.4), 10 mM MgCl₂, and 10 μM peptide (for Sox peptides λ_{ex} =360 nm; for Clk peptides λ_{ex} =375 nm).

Fig. 5




Fig. 6A




Fig. 6B

5/19

Kinase	Peptide	Peptide Sequence	Mol. Formula	HPLC t_R (min) ^b	[M] Calcd.	[M+H] ⁺ found ^c	
MK2	P1 ^a	Ac-AHLQRQLSI-CSox-HH-CONH ₂					SEQ ID NO:5
		Ac-AHLQRQLpSI-CSox-HH-CONH ₂					SEQ ID NO:1
	P2	Ac-AHLQRQLSI-CCIk-HH-CONH ₂	C ₈₁ H ₁₁₃ BrN ₂₈ O ₁₇ S	21.32	1862.91	1863.38	SEQ ID NO:6
		Ac-AHLQRQLpSI-CCIk-HH-CONH ₂	C ₈₁ H ₁₁₃ BrN ₂₈ O ₂₀ PS	23.45	1942.89	1943.22	SEQ ID NO:2
Src	P3 ^a	Ac-AEE-CSox-IYGEFEAKKKK-CONH ₂					SEQ ID NO:7
		Ac-AEE-CSox-IpYGEFEAKKKK-CONH ₂					SEQ ID NO:3
	P4	Ac-AEE-CCIk-IYGEFEAKKKK-CONH ₂	C ₉₉ H ₁₃₉ BrN ₂₄ O ₂₆ S	22.00	2193.28	2194.45	SEQ ID NO:8
		Ac-AEE-CCIk-IpYGEFEAKKKK-CONH ₂	C ₉₉ H ₁₄₀ BrN ₂₄ O ₂₉ PS	21.86	2273.26	2274.96	SEQ ID NO:4

^aThe synthesis and characterization of peptides P1 and P3 has been described.⁷ ^bReported retention times (t_R) and HPLC conditions are from analytical runs. Method: 5% B (5 min) followed by an increase to 15% B (1 min) and a linear gradient to 15-45% B (30 min). ^cThe data was collected on a MALDI-TOF mass spectrometer.

Fig. 7

Compound	λ_{ex} (nm)	λ_{em} (nm)	Φ^a
10a	371	522	0.033
10b	370	525	0.041
10c	367	523	0.043
10d	365	525	0.071
10e	365	520	-
10f	365	525	-
10g	365	525	-
10h	365	510	-
10i	375	525	0.067
10j	365	525	-
10k	365	525	-
10l	360	520	-
10m	360	525	-
10n	365	515	-
10o	360	510	-
10p	360	520	-
10q	365	515	-
10r	360	520	-
10s	360	530	-
10t	360	525	-
10u ^b	375	525	0.111
10v	365	520	-

^aQuantum yields of selected fluorophores were calculated with reference to quinine sulphate (in 0.05 M H₂SO₄) as a standard (*vide infra*). ^bExtinction coefficient: $\epsilon_{355} = 7905 \text{ cm}^{-1} \text{ M}^{-1}$ (*vide infra*).

Fig. 8

6/19




Fig. 9

7/19




Fig. 10

8/19




Fig. 11

9/19




Fig. 12

10/19




Fig. 13

11/19




Fig. 14

12/19




Fig. 15

13/19




Fig. 16

14/19




Fig. 17

15/19




Fig. 18

16/19




Fig. 19

17/19




Fig. 20

18/19




Fig. 21

19/19




Fig. 22

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2010/002384

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D249/06 C12Q1/48 G01N33/58 C07D403/02
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, Sequence Search, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GOPI HOSAHUDYA ET AL: "Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 9, May 2008 (2008-05), pages 2638-2647, XP002611833, ISSN: 0022-2623	2,3
Y	page 2640, table 1; page 2641, figure 1	2-4,8
A	----- -/--	1,5,9

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 November 2010

Date of mailing of the international search report

16/12/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Hennard, Christophe

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2010/002384

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KNOR S ET AL: CHEMISTRY - A EUROPEAN JOURNAL 2007 WILEY-VCH VERLAG DE, vol. 13, no. 21, 2007, pages 6082-6089, XP002611834, DOI: DOI:10.1002/CHEM.200700231 page 6086, compound 19	2,3
Y		2-4,8
A		1,5,9
X	US 2006/135746 A1 (HOSAHUDYA GOPI [US] ET AL) 22 June 2006 (2006-06-22)	2,3
Y	page 2, tabl 1; figure 1b	2-4,8
A		1,5,9
X	WO 2008/144223 A2 (LILLY CO ELI [US]; BROOKS HAROLD BURNS [US]; CRICH JOYCE Z [US]; HENRY) 27 November 2008 (2008-11-27) page 61, example 95	2
X	CHEN C-A ET AL: "Biosensors of protein kinase action: from in vitro assays to living cells", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, vol. 1697, no. 1-2, 11 March 2004 (2004-03-11), pages 39-51, XP004496036, ISSN: 1570-9639, DOI: DOI:10.1016/J.BBAPAP.2003.11.012 page 41, paragraph 4; page 49, figure 3	6,7
Y		2-4,8
A		1,5,9
X	WO 2009/000965 A1 (TURUN YLIOPISTO [FI]; NIEMELAE PAULIINA [FI]; SOUKKA TERO [FI]; APPELB) 31 December 2008 (2008-12-31)	6,7
Y	page 14, lines 5-19	2-4,8
A		1,5,9
X	US 5 912 137 A (TSIEN ROGER Y [US] ET AL) 15 June 1999 (1999-06-15)	6,7
Y	claims; column 11, table 1	2-4,8
A		1,5,9
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2010/002384

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	GONZÁLEZ-VERA JUAN A ET AL: "Synthesis of red-shifted 8-hydroxyquinoline derivatives using click chemistry and their incorporation into phosphorylation chemosensors.", THE JOURNAL OF ORGANIC CHEMISTRY 2 OCT 2009 LNKD- PUBMED:19725503, vol. 74, no. 19, 2 October 2009 (2009-10-02), pages 7309-7314, XP002611835, ISSN: 1520-6904 page 7310, figure 1; table 1; page 7312, scheme 2 and table 3	1-9
A	----- GONÇALVES M SAMEIRO T: "Fluorescent labeling of biomolecules with organic probes.", CHEMICAL REVIEWS JAN 2009 LNKD- PUBMED:19105748, vol. 109, no. 1, January 2009 (2009-01), pages 190-212, XP002611836, ISSN: 1520-6890 pages 197-206 -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2010/002384

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2006135746 A1	22-06-2006	US 2009191630 A1 US 2010099188 A1	30-07-2009 22-04-2010
WO 2008144223 A2	27-11-2008	AR 066473 A1 AU 2008254319 A1 CA 2691997 A1 CN 101679395 A EA 200971068 A1 EP 2155734 A2 JP 2010527365 T KR 20090130242 A PE 02162009 A1 US 2010087431 A1	19-08-2009 27-11-2008 27-11-2008 24-03-2010 30-04-2010 24-02-2010 12-08-2010 21-12-2009 28-02-2009 08-04-2010
WO 2009000965 A1	31-12-2008	NONE	
US 5912137 A	15-06-1999	US 6248550 B1	19-06-2001